Rajbharan Yadav

Dr. Rajbharan Yadav

Genentech Inc, South San Francisco, California, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
TSTianhe Sun
Tianhe Sun
ZHZhiyu Huang
Zhiyu Huang
WLWei-Ching Liang
Wei-Ching Liang
JYJianping Yin
Jianping Yin
WLWei Yu Lin
Wei Yu Lin
JAJoseph R. Arron
Joseph R. Arron
TGFβ2 and TGFβ3 isoforms are activated via unique mechanisms and are associated with fibrosis in human diseases.

1 April 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
Jürgen B. BulittaJürgen B. Bulitta
Jürgen B. Bulitta
NLNeang S. Ly
Neang S. Ly
Cornelia B. LandersdorferCornelia B. Landersdorfer
Cornelia B. Landersdorfer
NWNicholin A. Wanigaratne
Nicholin A. Wanigaratne
TVTony Velkov
Tony Velkov
BTBrian T. Tsuji
Brian T. Tsuji
Bacterial resistance is among the most serious threats to human health globally, and many bacterial isolates have emerged that are resistant to all antibiotics in monotherapy. Aminoglycosides are often used in combination therapies against severe infections by multidrug-resistant bacteria. However, models quantifying different antibacterial effects of aminoglycosides are lacking. While the mode of aminoglycoside action on protein synthesis has often been studied, their disruptive action on the outer membrane of Gram-negative bacteria remains poorly characterized. Here, we developed a novel quantitative model for these two mechanisms of aminoglycoside action, phenotypic tolerance at high bacterial densities, and adaptive bacterial resistance in response to an aminoglycoside (tobramycin) against three Pseudomonas aeruginosa strains. At low-intermediate tobramycin concentrations (<4 mg/liter), bacterial killing due to the effect on protein synthesis was most important, whereas disruption of the outer membrane was the predominant killing mechanism at higher tobramycin concentrations (≥8 mg/liter). The extent of killing was comparable across all inocula; however, the rate of bacterial killing and growth was substantially lower at the 10 8.9 CFU/ml inoculum than that at the lower inocula. At 1 to 4 mg/liter tobramycin for strain PAO1-RH, there was a 0.5- to 6-h lag time of killing that was modeled via the time to synthesize hypothetical lethal protein(s). Disruption of the outer bacterial membrane by tobramycin may be critical to enhance the target site penetration of antibiotics used in synergistic combinations with aminoglycosides and thereby combat multidrug-resistant bacteria. The two mechanisms of aminoglycoside action and the new quantitative model hold great promise to rationally design novel, synergistic aminoglycoside combination dosage regimens.

1 April 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
RYRajbharan Yadav
Rajbharan Yadav
Cornelia B. LandersdorferCornelia B. Landersdorfer
Cornelia B. Landersdorfer
RNRoger Nation
Roger Nation
JBJohn Boyce
John Boyce
Jürgen B. BulittaJürgen B. Bulitta
Jürgen B. Bulitta
Acinetobacter baumannii is among the most dangerous pathogens and emergence of resistance is highly problematic. Our objective was to identify and rationally optimize β-lactam-plus-aminoglycoside combinations via novel mechanism-based modeling that synergistically kill and prevent resistance of carbapenem-resistant A. baumannii . We studied combinations of 10 β-lactams and three aminoglycosides against four A. baumannii strains, including two imipenem-intermediate (MIC, 4 mg/liter) and one imipenem-resistant (MIC, 32 mg/liter) clinical isolate, using high-inoculum static-concentration time-kill studies. We present the first application of mechanism-based modeling for killing and resistance of A. baumannii using Monte Carlo simulations of human pharmacokinetics to rationally optimize combination dosage regimens for immunocompromised, critically ill patients. All monotherapies achieved limited killing (≤2.3 log 10 ) of A. baumannii ATCC 19606 followed by extensive regrowth for aminoglycosides. Against this strain, imipenem-plus-aminoglycoside combinations yielded more rapid and extensive killing than other β-lactam-plus-aminoglycoside combinations. Imipenem at 8 mg/liter combined with an aminoglycoside yielded synergistic killing (>5 log 10 ) and prevented regrowth of all four strains. Modeling demonstrated that imipenem likely killed the aminoglycoside-resistant population and vice versa and that aminoglycosides enhanced the target site penetration of imipenem. Against carbapenem-resistant A. baumannii (MIC, 32 mg/liter), optimized combination regimens (imipenem at 4 g/day as a continuous infusion plus tobramycin at 7 mg/kg of body weight every 24 h) were predicted to achieve >5 log 10 killing without regrowth in 98.2% of patients. Bacterial killing and suppression of regrowth were best achieved for combination regimens with unbound imipenem steady-state concentrations of at least 8 mg/liter. Imipenem-plus-aminoglycoside combination regimens are highly promising and warrant further evaluation.

12 January 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
SHSarah E. Headland
Sarah E. Headland
HDHart S. Dengler
Hart S. Dengler
DXDaqi Xu
Daqi Xu
GTGrace Teng
Grace Teng
CEChristine Everett
Christine Everett
MWMark Wilson
Mark Wilson
Bacterial-associated LPS drives oncostatin M–dependent airway inflammation and mucus hypersecretion in severe asthma.

1 December 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
RYRajbharan Yadav
Rajbharan Yadav
Jürgen B. BulittaJürgen B. Bulitta
Jürgen B. Bulitta
ESElena Katharina Schneider
Elena Katharina Schneider
BSBeom Soo Shin
Beom Soo Shin
TVTony Velkov
Tony Velkov
Cornelia B. LandersdorferCornelia B. Landersdorfer
Cornelia B. Landersdorfer
This study aimed to systematically identify the aminoglycoside concentrations required for synergy with a carbapenem and characterize the permeabilizing effect of aminoglycosides on the outer membrane of Pseudomonas aeruginosa . Monotherapies and combinations of four aminoglycosides and three carbapenems were studied for activity against P. aeruginosa strain AH298-GFP in 48-h static-concentration time-kill studies (SCTK) (inoculum: 10 7.6 CFU/ml). The outer membrane-permeabilizing effect of tobramycin alone and in combination with imipenem was characterized via electron microscopy, confocal imaging, and the nitrocefin assay. A mechanism-based model (MBM) was developed to simultaneously describe the time course of bacterial killing and prevention of regrowth by imipenem combined with each of the four aminoglycosides. Notably, 0.25 mg/liter of tobramycin, which was inactive in monotherapy, achieved synergy (i.e., ≥2-log 10 more killing than the most active monotherapy at 24 h) combined with imipenem. Electron micrographs, confocal image analyses, and the nitrocefin uptake data showed distinct outer membrane damage by tobramycin, which was more extensive for the combination with imipenem. The MBM indicated that aminoglycosides enhanced the imipenem target site concentration up to 4.27-fold. Tobramycin was the most potent aminoglycoside to permeabilize the outer membrane; tobramycin (0.216 mg/liter), gentamicin (0.739 mg/liter), amikacin (1.70 mg/liter), or streptomycin (5.19 mg/liter) was required for half-maximal permeabilization. In summary, our SCTK, mechanistic studies and MBM indicated that tobramycin was highly synergistic and displayed the maximum outer membrane disruption potential among the tested aminoglycosides. These findings support the optimization of highly promising antibiotic combination dosage regimens for critically ill patients.

1 April 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
Cornelia B. LandersdorferCornelia B. Landersdorfer
Cornelia B. Landersdorfer
VRVanessa E. Rees
Vanessa E. Rees
RYRajbharan Yadav
Rajbharan Yadav
KRKate E. Rogers
Kate E. Rogers
TKTae Hwan Kim
Tae Hwan Kim
Jürgen B. BulittaJürgen B. Bulitta
Jürgen B. Bulitta
HypermutablePseudomonas aeruginosastrains are prevalent in patients with cystic fibrosis and rapidly become resistant to antibiotic monotherapies. Combination dosage regimens have not been optimized against such strains using mechanism-based modeling (MBM) and the hollow-fiber infection model (HFIM). The PAO1 wild-type strain and its isogenic hypermutable PAOΔmutSstrain (MICmeropenemof 1.0 mg/liter and MICtobramycinof 0.5 mg/liter for both) were assessed using 96-h static-concentration time-kill studies (SCTK) and 10-day HFIM studies (inoculum, ∼108.4CFU/ml). MBM of SCTK data were performed to predict expected HFIM outcomes. Regimens studied in the HFIM were meropenem at 1 g every 8 h (0.5-h infusion), meropenem at 3 g/day with continuous infusion, tobramycin at 10 mg/kg of body weight every 24 h (1-h infusion), and both combinations. Meropenem regimens delivered the same total daily dose. Time courses of total and less susceptible populations and MICs were determined. For the PAOΔmutSstrain in the HFIM, all monotherapies resulted in rapid regrowth to >108.7CFU/ml with near-complete replacement by less susceptible bacteria by day 3. Meropenem every 8 h with tobramycin caused >7-log10bacterial killing followed by regrowth to >6 log10CFU/ml by day 5 and high-level resistance (MICmeropenem, 32 mg/liter; MICtobramycin, 8 mg/liter). Continuous infusion of meropenem with tobramycin achieved >8-log10bacterial killing without regrowth. For PAO1, meropenem monotherapies suppressed bacterial growth to <4 log10over 7 to 9 days, with both combination regimens achieving near eradication. An MBM-optimized meropenem plus tobramycin regimen achieved synergistic killing and resistance suppression against a difficult-to-treat hypermutableP. aeruginosastrain. For the combination to be maximally effective, it was critical to achieve the optimal shape of the concentration-time profile for meropenem.